Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.07.004 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Ellen Lewis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada.
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Department of Pathology and Lab Medicine, Department of Medicine, University of Calgary, Calgary, AB, Ca…
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre/University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. Electronic addr…
Zitieren
APA
Lewis, E., McCulloch, S., Mahe, E., Bahlis, N., Neri, P., Tay, J., Duggan, P., & Jimenez-Zepeda, V. H. (2023). Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.07.004
Vancouver
Lewis E, McCulloch S, Mahe E, Bahlis N, Neri P, Tay J, et al. Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.07.004
BibTeX
@article{Lewis2023,
author = {Lewis, Ellen and McCulloch, Sylvia and Mahe, Etienne and Bahlis, Nizar and Neri, Paola and Tay, Jason and Duggan, Peter and Jimenez-Zepeda, Victor H},
title = {Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.07.004}
}
EUVIMED